This list is an analysis based on recent market events. It's not an investment recommendation.
About
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
The current price of EX1.AU is A$0.01 AUD — it has increased by +0% in the past 24 hours. Watch Exopharm Limited stock price performance more closely on the chart.
What is Exopharm Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Australia Exchange exchange Exopharm Limited stocks are traded under the ticker EX1.AU.
What is Exopharm Limited market cap?▼
Today Exopharm Limited has the market capitalization of 18.5M
What is Exopharm Limited revenue for the last year?▼
Exopharm Limited revenue for the last year amounts to 0 AUD.
What is Exopharm Limited net income for the last year?▼
EX1.AU net income for the last year is -4.87M AUD.
How many employees does Exopharm Limited have?▼
As of November 2, 2026, the company has 4 employees.
In which sector is Exopharm Limited located?▼
Exopharm Limited operates in the Health & Wellness sector.
When did Exopharm Limited complete a stock split?▼
The last stock split for Exopharm Limited was on April 15, 2024 with a ratio of 1:2.5.
Where is Exopharm Limited headquartered?▼
Exopharm Limited is headquartered in Hawthorn East, Australia.